HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

21 يونيو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

16 يونيو 2024 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

06 يونيو 2024 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

02 يونيو 2024 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

23 مايو 2024 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

17 مايو 2024 10:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

16 مايو 2024 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

13 مايو 2024 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

13 مايو 2024 20:00:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

10 مايو 2024 09:45:09 بحسب NetDania Notify

NetDania - New 12 months High: HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

09 مايو 2024 09:45:13 بحسب NetDania Notify

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

08 مايو 2024 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

26 أبريل 2024 08:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

05 أبريل 2024 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

02 أبريل 2024 00:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

27 مارس 2024 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

21 مارس 2024 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

28 فبراير 2024 06:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

06 فبراير 2024 19:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

02 فبراير 2024 03:30:00 بحسب Nasdaq GlobeNewswire